Cue Biopharma Inc Stock Price, News & Analysis

Cue Biopharma (CUE) announced interim clinical data from its Phase 1a/1b study of CUE-101, showing a confirmed partial response (PR) in a patient with HPV+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This marks initial clinical proof of concept for its Immuno-STAT™ platform, highlighting activity in modulating the anti-tumor T-cell repertoire. The study reported favorable tolerability and evidence of immune cell activation. The company plans to discuss these findings in its upcoming quarterly update on May 17, 2021.

On May 6, 2021, Cue Biopharma (Nasdaq: CUE) announced it will present at the virtual New York Academy of Sciences 2021 Frontiers in Cancer Immunotherapy meeting from May 12-14, 2021. The presentation will focus on the Immuno-STAT™ platform, designed to enhance anti-tumor immune responses, alongside its expanding pipeline including lead candidate CUE-101, which targets HPV+ head and neck squamous cell carcinoma. Dr. Steve Quayle will discuss clinical data demonstrating favorable activity for CUE-101 and introduce CUE-102, targeting WT1, expected to enter clinical trials in 2022.

Cue Biopharma provided a business update for Q4 and full-year 2020, focusing on their ongoing clinical trials and financial performance. The company initiated the Phase 1 trial for CUE-101, both as monotherapy and in combination with KEYTRUDA, showing promising early results in treating HPV+ R/M HNSCC. However, collaboration revenues decreased from $3.5 million in 2019 to $3.2 million in 2020. R&D expenses rose to $33.5 million, reflecting increased clinical activity, and the company reported a net loss of $44.8 million.

Cue Biopharma (Nasdaq: CUE) announced its participation in the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. The company will present a corporate update on March 18, 2021, at 9:20 a.m. EDT, focusing on the clinical progress of CUE-101, its lead therapeutic for HPV+ recurrent/metastatic head and neck cancer. Additionally, they will discuss advancements in the CUE-400 series, targeting various autoimmune diseases. The presentation will be available via webcast and archived for 30 days on their website.

Cue Biopharma, based in Cambridge, Massachusetts, announced a conference call on March 16, 2021, at 4:30 p.m. EDT, to provide a business update. The call will cover updates on the CUE-101 Phase 1 dose escalation trial and the KEYNOTE-A78 combination trial with KEYTRUDA for HPV+ recurrent head and neck cancer. Additionally, the management will discuss pipeline developments and strategic milestones. Investors can join via phone or webcast, with details available on the company’s website.

Cue Biopharma, a clinical-stage biopharmaceutical company, announced its participation in the Cowen 41st Annual Health Care Conference from March 1-4, 2021. The company will present an overview of its innovative Immuno-STAT™ platform, highlighting key developments, including updates on its Phase 1 trial for CUE-101 monotherapy and its combination trial with KEYTRUDA® for treating HPV+ recurrent/metastatic head and neck cancer. The presentation is scheduled for March 4, 2021, at 9:10 a.m. EST, and will be available via webcast.

On February 25, 2021, Cue Biopharma announced the appointment of Dr. Abul K. Abbas and Dr. Michael Kalos to its Scientific Advisory Board. These appointments aim to enhance the company’s capabilities in advancing its immune modulation technologies. Dr. Abbas, an expert in immunology, and Dr. Kalos, a leader in T cell therapy, are expected to provide strategic guidance to boost Cue Biopharma’s research and drug development efforts. Their combined experience is anticipated to facilitate the development of treatments targeting cancer and autoimmune diseases through the company's proprietary platforms Immuno-STAT™ and Neo-STAT™.

On February 22, 2021, Cue Biopharma (NASDAQ: CUE) announced that Dr. Anish Suri, president and chief scientific officer, will present at the 7th Annual Immuno-Oncology 360° Conference on February 25, 2021. He will discuss the Immuno-STAT™ platform, focusing on the CUE-100 series, which includes CUE-101 and CUE-102, targeting T cells for cancer treatments. The presentation aims to show the mechanistic advantages of this approach, offering a novel way to engage T cells in vivo. The event will also include a panel on vaccine expert discussions.

Cue Biopharma has appointed Dr. Matteo Levisetti as Senior Vice President of Clinical Development, effective February 22, 2021. Dr. Levisetti brings extensive experience in drug development from his roles at prominent pharmaceutical companies. He will oversee Cue Biopharma’s ongoing CUE-101 Phase 1 dose escalation trial and the combination trial KEYNOTE-A78, evaluating CUE-101 with KEYTRUDA® for HPV+ R/M HNSCC. Additionally, he will assist in the CUE-102/A02 program targeting WT1 specific T cells. The appointment aims to strengthen the company's immunotherapy pipeline.